Telesis Bio Q2 EPS $(0.28) Beats $(0.32) Estimate, Sales $8.65M Beat $8.60M Estimate
Portfolio Pulse from Benzinga Newsdesk
Telesis Bio (NASDAQ:TBIO) reported Q2 earnings per share (EPS) of $(0.28), beating the analyst consensus estimate of $(0.32) by 12.5%. This is a 44% increase over losses from the same period last year. The company also reported quarterly sales of $8.65 million, beating the estimate of $8.60 million by 0.60%. This is a 53% increase over sales from the same period last year.
August 10, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Telesis Bio's Q2 earnings and sales beat estimates, indicating a positive financial performance. This could potentially lead to a positive impact on the company's stock.
Telesis Bio reported better than expected Q2 earnings and sales, which is typically a positive signal for investors. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100